OCUL vs PSA · rev $63.7M vs rev $4.82B
Ocular Therapeutix Inc (OCUL) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Ocular Therapeutix Inc (OCUL) is a biotechnology company listed on US.
PSA (PSA) common stock.
Latest reported OCUL revenue for 2024-12-31 was $63.7M. Net income was -$193.5M. Revenue was up 9.0% from 2023-12-31 to 2024-12-31. OCUL currently screens at market cap $1.76B.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
OCUL currently screens at market cap $1.76B. PSA currently screens at market cap $0.
Not investment advice. Open the OCUL and PSA stock pages for the full models.
Not investment advice.